Sign in
MBRX Stock Price, Chart, Stats & News
Moleculin Biotech, Inc.
Save
Moleculin Biotech, Inc. (MBRX) does not currently pay a dividend.
3.21M
Market cap
–
Current P/E
–
Forward P/E
MBRX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -108.12% |
ROE | 502.66% |
D/E | 0.02x |
Interest coverage ratio | – |
MBRX valuation
P/E | – |
P/S | – |
P/B | 1.93x |
P/CF | -1.27x |
P/FCF | -0.13x |
P/OCF | -1.27x |
PEG | -1.13x |
EV multiple | -0.46x |
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Similar securities
Based on sector and market capitalization
Report issue